Abdominal obesity is a risk factor for dysexecutive function in chronic kidney disease

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The aim of this study was to assess the influence of the metabolic syndrome and its components on dysexecutive function (DF) in individuals with and without CKD. Among 588 participants aged over 70 from the Einstein Aging Study (EAS), we defined DF as performance of 2SDs below the mean on any one test or 1.5SDs below the mean on any two of the following: Block Design, Digit Symbol Coding and the Trail-making Tests A and B. We defined CKD as an eGFR below 60 mL/min/m2. MetS was defined according to recent guidelines from the National Cholesterol Education Program. 149 participants had CKD at cross-section, 16.1% of which also showed DF. Of the 439 participants without CKD, 12.3% displayed DF. Abdominal obesity as measured by waist circumference, was an independent risk factor for dysexecutive function in CKD (OR = 14.3, 95%CI = 2.21-91.93, p = 0.005) but not in non-CKD. None of the other MetS components were associated with DF. Results suggested that abdominal obesity, recognized as an integral part of the MetS, is a strong risk factor for DF in individuals with CKD.

Original languageEnglish (US)
Pages (from-to)128-133
Number of pages6
JournalPreventive Medicine Reports
Volume4
DOIs
StatePublished - Dec 1 2016

Fingerprint

Abdominal Obesity
Chronic Renal Insufficiency
Trail Making Test
Waist Circumference
Cholesterol
Guidelines
Education

Keywords

  • Abdominal obesity
  • Chronic kidney disease
  • Dysexecutive function
  • Metabolic syndrome

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Health Informatics

Cite this

@article{f564e63aabe54b87b3680687b1c80a45,
title = "Abdominal obesity is a risk factor for dysexecutive function in chronic kidney disease",
abstract = "The aim of this study was to assess the influence of the metabolic syndrome and its components on dysexecutive function (DF) in individuals with and without CKD. Among 588 participants aged over 70 from the Einstein Aging Study (EAS), we defined DF as performance of 2SDs below the mean on any one test or 1.5SDs below the mean on any two of the following: Block Design, Digit Symbol Coding and the Trail-making Tests A and B. We defined CKD as an eGFR below 60 mL/min/m2. MetS was defined according to recent guidelines from the National Cholesterol Education Program. 149 participants had CKD at cross-section, 16.1{\%} of which also showed DF. Of the 439 participants without CKD, 12.3{\%} displayed DF. Abdominal obesity as measured by waist circumference, was an independent risk factor for dysexecutive function in CKD (OR = 14.3, 95{\%}CI = 2.21-91.93, p = 0.005) but not in non-CKD. None of the other MetS components were associated with DF. Results suggested that abdominal obesity, recognized as an integral part of the MetS, is a strong risk factor for DF in individuals with CKD.",
keywords = "Abdominal obesity, Chronic kidney disease, Dysexecutive function, Metabolic syndrome",
author = "Zammit, {Andrea R.} and Katz, {Mindy Joy} and Derby, {Carol A.} and Markus Bitzer and Lipton, {Richard B.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.pmedr.2016.06.007",
language = "English (US)",
volume = "4",
pages = "128--133",
journal = "Preventive Medicine Reports",
issn = "2211-3355",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Abdominal obesity is a risk factor for dysexecutive function in chronic kidney disease

AU - Zammit, Andrea R.

AU - Katz, Mindy Joy

AU - Derby, Carol A.

AU - Bitzer, Markus

AU - Lipton, Richard B.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The aim of this study was to assess the influence of the metabolic syndrome and its components on dysexecutive function (DF) in individuals with and without CKD. Among 588 participants aged over 70 from the Einstein Aging Study (EAS), we defined DF as performance of 2SDs below the mean on any one test or 1.5SDs below the mean on any two of the following: Block Design, Digit Symbol Coding and the Trail-making Tests A and B. We defined CKD as an eGFR below 60 mL/min/m2. MetS was defined according to recent guidelines from the National Cholesterol Education Program. 149 participants had CKD at cross-section, 16.1% of which also showed DF. Of the 439 participants without CKD, 12.3% displayed DF. Abdominal obesity as measured by waist circumference, was an independent risk factor for dysexecutive function in CKD (OR = 14.3, 95%CI = 2.21-91.93, p = 0.005) but not in non-CKD. None of the other MetS components were associated with DF. Results suggested that abdominal obesity, recognized as an integral part of the MetS, is a strong risk factor for DF in individuals with CKD.

AB - The aim of this study was to assess the influence of the metabolic syndrome and its components on dysexecutive function (DF) in individuals with and without CKD. Among 588 participants aged over 70 from the Einstein Aging Study (EAS), we defined DF as performance of 2SDs below the mean on any one test or 1.5SDs below the mean on any two of the following: Block Design, Digit Symbol Coding and the Trail-making Tests A and B. We defined CKD as an eGFR below 60 mL/min/m2. MetS was defined according to recent guidelines from the National Cholesterol Education Program. 149 participants had CKD at cross-section, 16.1% of which also showed DF. Of the 439 participants without CKD, 12.3% displayed DF. Abdominal obesity as measured by waist circumference, was an independent risk factor for dysexecutive function in CKD (OR = 14.3, 95%CI = 2.21-91.93, p = 0.005) but not in non-CKD. None of the other MetS components were associated with DF. Results suggested that abdominal obesity, recognized as an integral part of the MetS, is a strong risk factor for DF in individuals with CKD.

KW - Abdominal obesity

KW - Chronic kidney disease

KW - Dysexecutive function

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=84973582178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973582178&partnerID=8YFLogxK

U2 - 10.1016/j.pmedr.2016.06.007

DO - 10.1016/j.pmedr.2016.06.007

M3 - Article

VL - 4

SP - 128

EP - 133

JO - Preventive Medicine Reports

JF - Preventive Medicine Reports

SN - 2211-3355

ER -